An article from

Jonathan Gardner

[email protected]

184 articles by Jonathan Gardner

Filter by Month:

Lilly seeking out more 'Dermira-like' deals: report
Jan. 17, 2020
Civica advances drug supply strategy with Thermo Fisher deal
Jan. 16, 2020
Astellas swoops in for Adaptimmune deal a day after positive data
Jan. 14, 2020
Biogen finds $75M home for Pfizer Alzheimer's drug
Jan. 13, 2020
Ultragenyx boosted by trial data for 2nd gene therapy
Jan. 10, 2020
5 trends to watch at the FDA in 2020
Jan. 9, 2020
Solid cuts one-third of staff, goes all in on delayed gene therapy
Jan. 9, 2020
AbbVie to house Allergan Botox business in separate unit
Jan. 8, 2020
Merck's Keytruda falls short of rivals in 1 lung cancer type
Jan. 7, 2020
Merck adds to lung cancer wall with Otsuka deal
Jan. 6, 2020
Wave's Huntington's drug shows effect but falls short of mark set by Roche and Ionis
Jan. 2, 2020
AstraZeneca and Merck's Lynparza cleared by FDA for pancreatic cancer
Dec. 30, 2019
Roche hands $1B to Sarepta in major return to gene therapy deals
Dec. 23, 2019
Daiichi, AstraZeneca breast cancer drug joins bumper crop of early FDA approvals
Dec. 20, 2019
AstraZeneca lupus drug shows potential, but it may not be enough for FDA
Dec. 19, 2019
Muscle data doesn't help Solid build faith in its gene therapy
Dec. 18, 2019
BeiGene's Brukinsa bet falls short against Imbruvica
Dec. 16, 2019
Wave cancels its Exondys competitor and heads back to the lab in muscular dystrophy
Dec. 16, 2019
In stunning twist, FDA approves Sarepta's Duchenne drug it rejected
Dec. 12, 2019
House passes drug pricing bill that pharma warned would bring 'nuclear winter'
Dec. 12, 2019
Value-based pricing for gene therapy? Maybe not ready for hemophilia
Dec. 11, 2019
UniQure, Pfizer updates hint at gene therapy potential in hemophilia B
Dec. 10, 2019
Leukemia rivals try to stay ahead as Merck, Lilly chase
Dec. 10, 2019
As CAR-T presses ahead in multiple myeloma, alternative approaches gain supporters
Dec. 9, 2019
Disruptor of the Year: The Federal Trade Commission
Dec. 9, 2019
Pharma of the Year: AstraZeneca
Dec. 9, 2019
We're not for sale, Alexion executives declare
Dec. 6, 2019
Cancer gene therapy backed by Blackstone gets trial win
Dec. 5, 2019
New approval for Roche's Tecentriq heats up lung cancer battle with Keytruda
Dec. 4, 2019
Will sky-high drug prices spur the US to use an obscure power over patents?
Dec. 4, 2019
Opioid makers subject of US grand jury probe
Nov. 27, 2019
Global Blood's sickle cell drug wins FDA approval, joining Novartis' Adakveo
Nov. 25, 2019
What Novartis needs to do to make Medicines Co. deal a success
Nov. 25, 2019
Calquence OK boosts AstraZeneca's challenge to Imbruvica
Nov. 22, 2019
FDA's rapid review pace nets an early approval for Alnylam's second drug
Nov. 20, 2019
France clears way for wide use of Vertex's Orkambi
Nov. 20, 2019
Alkermes follows up restructuring with Rodin acqusition
Nov. 18, 2019
Novartis sickle cell drug wins FDA approval
Nov. 15, 2019
BeiGene FDA cancer drug nod seen as breakthrough for Chinese biopharma
Nov. 15, 2019
Sarepta brings in more gene therapies with StrideBio deal
Nov. 14, 2019
ICER draws new gene therapy pricing framework
Nov. 13, 2019
Solid gene therapy trial halted again by FDA
Nov. 12, 2019
Roche's oral SMA drug scores in older patients
Nov. 11, 2019
Fibrogen, AstraZeneca confirm roxadustat's heart safety months after confusing first readout
Nov. 8, 2019
Sarepta tries softer approach to resolve FDA setback
Nov. 8, 2019
Celgene's last hurrah at ASH a defining moment for Bristol-Myers' buyout
Nov. 7, 2019
AstraZeneca's China ambitions grow with new R&D investments
Nov. 6, 2019
Third Neulasta biosimilar on its way as Sandoz wins long-delayed FDA approval
Nov. 5, 2019
Halozyme laying off 160 after pancreatic cancer trial comes up short
Nov. 4, 2019
Amgen's China ambitions become clear with BeiGene deal
Nov. 1, 2019
Sanofi pays $315 million to settle Lemtrada go-slow claims
Oct. 31, 2019
Novartis gene therapy ambitions dealt another blow by FDA hold on Zolgensma
Oct. 30, 2019
AstraZeneca joins Bristol-Myers' run at Merck in lung cancer
Oct. 28, 2019
Allergan pays $750M to rid itself of Namenda antitrust charges
Oct. 28, 2019
AstraZeneca blood cancer drug heading for showdown with AbbVie's
Oct. 24, 2019
Longtime Lilly diabetes chief Conterno to step down
Oct. 23, 2019
7 questions on Biogen's revival of a failed Alzheimer's drug
Oct. 22, 2019
Teva offers $23B of Suboxone to get out of opioid litigation
Oct. 21, 2019
Drug distributors, Teva settle in Ohio opioid case
Oct. 21, 2019
Merck's Ebola vaccine wins key European vote
Oct. 18, 2019
Give up board chairmanship? No thanks, US big pharma CEOs say
Oct. 16, 2019
Lilly shuttering UK neuroscience research site
Oct. 15, 2019
Pelosi drug plan would save $370B, but could reduce R&D, forecasters say
Oct. 14, 2019
On second thought, AbbVie's new arthritis drug not so costly, ICER says
Oct. 11, 2019
ProQR eye-disease data lend confidence that pivotal trial will succeed
Oct. 10, 2019
Feeling pressure in hemophilia, Novo signs gene editing deal with Bluebird
Oct. 9, 2019
Akcea inks deal with Pfizer, rebounding after leadership shuffle
Oct. 7, 2019
Sarepta, in shadow of FDA setback, marks gene therapy progress
Oct. 4, 2019
Amicus rare disease data build hope for approval
Oct. 2, 2019
FDA knocks back AstraZeneca's respiratory ambitions
Oct. 1, 2019
AstraZeneca, Merck strengthen lead in PARP drug class
Sept. 28, 2019
Medicines Co. gets cholesterol confirmation
Sept. 25, 2019
Clovis shares plunge after downgrade raises questions on path forward
Sept. 24, 2019
Amag fights activist investor's bid for board seats
Sept. 23, 2019
Is the future of diabetes treatment better drugs or better care?
Sept. 23, 2019
Novo gains approval for first oral diabetes drug of its kind
Sept. 20, 2019
The top drugs facing cuts under Pelosi's pricing plan
Sept. 20, 2019
House Democrats forge ahead with direct Medicare drug price negotiation
Sept. 19, 2019
Acceleron dealt pipeline setback
Sept. 17, 2019
5 questions ESMO cancer drug data might answer
Sept. 16, 2019
Another BACE dropped as Biogen and Eisai halt elenbecestat trials
Sept. 13, 2019
Adverum sinks on first gene therapy data for eye disease
Sept. 12, 2019
ICER dings Novo's new oral diabetes drug
Sept. 11, 2019
Medicare would negotiate prices for 250 drugs under House Democrats' plan
Sept. 10, 2019
Trial win could drive Acadia's Nuplazid to new use
Sept. 9, 2019
Roivant offloads biotech stakes in $3B alliance with Japanese pharma
Sept. 6, 2019
Novo Nordisk Foundation makes green grant to Danish-US university collaboration
Sept. 5, 2019
Ultragenyx gene therapy data disappoints investors
Sept. 5, 2019
Medicines Co.'s cholesterol drug looks good to take on PCSK9 rivals
Sept. 2, 2019
Novartis vies for multiple sclerosis dominance with Arzerra trial
Aug. 30, 2019
AstraZeneca gets lupus win but past failure could slow progress
Aug. 29, 2019
Amyloid's last hope? Prevention studies next big test for Alzheimer's research
Aug. 29, 2019
Immatics shows Celgene isn't done stocking cell therapy pipeline
Aug. 28, 2019
Gene editing companies oppose altering of embryos
Aug. 27, 2019
To patients, Sarepta repeats message on surprise rejection of Duchenne drug
Aug. 22, 2019
Sarepta now needs flawless progress for gene therapy
Aug. 20, 2019
Sarepta Duchenne drug rejected by FDA in surprise setback
Aug. 19, 2019
Pharming deal shows there's still life in struggling cancer drug class
Aug. 15, 2019
Regeneron gets cholesterol drug win where Praluent won't go
Aug. 14, 2019
Deciphera success sets up 2-horse race in gastrointestinal cancer
Aug. 13, 2019
AstraZeneca cancer drugs build as primary care shrinks
Aug. 12, 2019
Nektar battered over manufacturing issues and Bristol-Myers pullback
Aug. 9, 2019
Hospitalized gene therapy patient triggers Sarepta sell off
Aug. 8, 2019
Lilly shuffles executives overseeing oncology and M&A
Aug. 7, 2019
Teva finance chief resigns in midst of restructuring
Aug. 7, 2019
Amneal founders take reins as business struggles mount
Aug. 5, 2019
Sickle-cell setback triggers share slide at GlycoMimetics
Aug. 5, 2019
Takeda board lays out Shire integration goals
Aug. 2, 2019
Medicines Co. awaits its date with destiny
Aug. 1, 2019
White House backs importing drugs from abroad
July 31, 2019
How Mylan ended as a junior partner in its Pfizer deal
July 30, 2019
Mylan's tumble ends with Pfizer rescue
July 29, 2019
Senate advances drug pricing bill, setting up September vote
July 26, 2019
Roche highlights growth ahead of US biosimilar storm
July 25, 2019
Senate committee targets drug price increases with broad bill
July 23, 2019
Nonprofit US generics company secures supplier in Hikma
July 23, 2019
Opioid and price fixing legal liabilities mount for generic companies
July 22, 2019
Ultragenyx close to learning whether gene therapy gamble will pay off
July 19, 2019
MyoKardia cuts all ties to Sanofi
July 18, 2019
Merck urges caution on use of its newly approved antibacterial
July 17, 2019
Advocacy group pledges six-figure ad buy to support Trump drug price plan
July 17, 2019
Xarelto falls into the donut hole
July 16, 2019
AbbVie bets on early immuno-oncology asset
July 15, 2019
Amgen and Novartis halt Alzheimer's studies as faith in amyloid hypothesis dims
July 12, 2019
Billion-dollar settlement gets Reckitt out of federal opioid probes
July 11, 2019
In win for pharma, Trump TV drug price rule struck down
July 9, 2019
Roche acknowledges the obvious, extends Spark buyout deadline
July 8, 2019
Array pushed Pfizer for a higher price to get deal done
July 1, 2019
Pfizer muscular dystrophy gene therapy stumbles on safety
June 28, 2019
Zogenix boosted on FDA about-face for seizure drug application
June 27, 2019
AstraZeneca gets immuno-oncology win in a disease that Merck doesn't rule
June 27, 2019
AbbVie deal for Allergan not about the taxes, thanks to 2017 law
June 26, 2019
Novartis fights off generics courtroom challenge
June 25, 2019
Bristol-Myers price for Celgene now includes Otezla sell-off
June 24, 2019
Beating Keytruda a big task, Exelixis and Roche find
June 21, 2019
Sanofi to cut 466 workers in Europe as it seeks to refocus R&D
June 20, 2019
Pfizer goes big on targeted cancer therapies with $11.4B Array buy
June 17, 2019
Upadacitinib a plus for AbbVie in rheumatoid arthritis, doc survey says
June 14, 2019
Bluebird sets $1.8M price tag for blood-disease gene therapy
June 14, 2019
Savara lung disease trial misses, but execs vow to press on
June 13, 2019
FTC demands could mean months-long delay for Roche-Spark deal
June 12, 2019
Novo Nordisk goes for broke on semaglutide heart data
June 11, 2019
Trulicity heart data falls short for Lilly investors
June 10, 2019
Amicus widens UPenn gene therapy collaboration
May 29, 2019
BioMarin readies hemophilia gene therapy for FDA submission
May 28, 2019
Pay-for-delay deals disappearing, FTC says
May 24, 2019
Could Novartis' gene therapy have more than one price?
May 23, 2019
5 novel immuno-oncology targets to know before ASCO
May 22, 2019
No news is bad news for Tocagen
May 22, 2019
Array gets a win in colorectal cancer
May 21, 2019
Long-term heart data reassures for Medicines Co.
May 20, 2019
Medicare decides against tighter management of HIV drugs
May 17, 2019
Breast cancer survival data buoys Macrogenics and Puma
May 16, 2019
Cost-effectiveness agency clears Biogen's Spinraza for UK patients
May 15, 2019
Solid's gene therapy stumble makes Sarepta's lead clearer
May 14, 2019
Generics price-fixing lawsuit focuses on Teva's role as catalyst
May 13, 2019
Fibrogen confuses as it tries to explain blood-boosting drug data
May 10, 2019
Biopharma happily takes the tax cuts, but the jobs are harder to find
May 9, 2019
AstraZeneca's share dilution gamble on Daiichi drug pays off
May 8, 2019
Roche risdiplam data heats up SMA rivalry with Novartis
May 7, 2019
Novartis makes final Zolgensma pitch before FDA decision
May 6, 2019
Approval of $225,000-a-year tafamidis comes early for Pfizer
May 6, 2019
Rebate ban not a magic balm, federal budget forecasters say
May 3, 2019
Cost cuts to the rescue for Teva, so far
May 2, 2019
Generic Advair hits GSK revenues hard
May 1, 2019
Pfizer prospects for tafamidis market
April 30, 2019
Alexion, AstraZeneca secure backing of EMA panel for key drugs
April 29, 2019
Roche's takeout of Spark not working like a Swiss watch
April 26, 2019
Don't worry about Humira biosimilars, the pipeline will deliver, AbbVie says
April 25, 2019
Medicare proposes raising CAR-T pay, but reimbursement solution years away
April 24, 2019
Competition and donut hole discount takes toll on Xarelto sales
April 23, 2019
Safety setback for Pfizer, Lilly pain drug should have Regeneron and Teva feeling nervous
April 22, 2019
$300M loan boosts launch of TherapeuticsMD hot flash pill
April 18, 2019
Sarepta may have seen off another rival in Wave
April 17, 2019
Its ambitions restrained, Amgen sets modest Evenity price
April 16, 2019
Kidney data may give J&J diabetes drug an edge
April 15, 2019
Gilead and Novo Nordisk pair up to take on NASH
April 12, 2019
Intercept sputters as it reveals full Ocaliva NASH data to doctors
April 11, 2019
Indivior draws criminal indictment for opioid marketing practices
April 10, 2019
Pharmacy's 'middlemen' counter pharma's campaign to shift the price blame
April 9, 2019
Audentes lays down marker in muscular dystrophy
April 8, 2019
Copay assistance snares 3 drug companies in Medicare kickback charges
April 5, 2019
What to look for after Zolgensma's launch
April 4, 2019
Roche must ask Spark shareholders once again to sell
April 3, 2019

Home
- Pharma
- Biotech
- FDA
- Clinical Trials
- Deals
- Drug Pricing
- Gene Therapy
Deep Dive
Opinion
Library
Events

Get BioPharma Dive in your inbox

The free newsletter covering the top industry headlines

Select Newsletter: BioPharma Dive
Topics covered: Clinical trials, drug development, regulatory affairs, and much more.
Daily view sample
Select Newsletter: BioPharma Dive: Manufacturing Weekly view sample
Select Newsletter: BioPharma Dive: Marketing Weekly view sample

By signing up you agree to our privacy policy. You can opt out anytime.